Clearmind Medicine Inc. (CMND) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.6x

Market Cap

$1.72M

MomentumView details →

1D Return

−31.76%

YTD Return

−92.18%

RSI (14)

34.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.6x

Market Cap

$1.72M

RSI (14)

34.6

MomentumView details →

1D Return

−31.76%

YTD Return

−92.18%

SummaryUpdated Apr 1, 2026

Clearmind Medicine Inc. (NASDAQ:CMND) is a pre-clinical stage biotechnology company founded in 2017 and based in Vancouver, Canada. The company went public in November 2022 and focuses on developing novel psychedelic-based medicines to treat underserved mental health conditions. Originally incorporated as Cyntar Ventures Inc., the company changed its name to Clearmind Medicine Inc. in March 2021 to reflect its specialized focus on psychedelic therapeutics. As a pre-clinical company, Clearmind has not yet generated revenue and remains in the early stages of drug development.

Ask drillr about Clearmind Medicine Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−68.76%

ROA (TTM)

−54.40%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+74.75%

FCF YoY

−4.91%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+55.31%

EBITDA YoY

−18.00%

EarningsView details →

EPS (Actual)

−$6.78

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.79x

Quick Ratio

4.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−7.90M

Op. CF (TTM)

−6.76M

Latest newsMore news →

CLEARMIND MEDICINE signed a definitive agreement to acquire a 51% stake in a wireless charging company focused on automated parking and robotaxis.12h ago

Clearmind Medicine initiated Phase IIa of its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled at two medical centers in Israel.4d ago

Similar companies

Avenue Therapeutics, Inc.ATXI Protagenic Therapeutics, Inc.PTIX Decoy Therapeutics Inc.DCOY Silexion Therapeutics Ltd.SLXN Liminatus Pharma, Inc. WarrantsLIMNW Virax Biolabs Group LimitedVRAX Find similar companies →

Latest newsMore news →

CLEARMIND MEDICINE signed a definitive agreement to acquire a 51% stake in a wireless charging company focused on automated parking and robotaxis.12h ago Clearmind Medicine initiated Phase IIa of its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled at two medical centers in Israel.4d ago Clearmind Medicine announced the U.S. publication of a patent application covering MDMA-N-acylethanolamines for PTSD treatment, expanding IP from its collaboration with Neurothera Labs Inc.12d ago